Figure 1.

Progression-free survival (PFS) by plasma biomarker concentration. (A) Bevacizumab 7.5 mg kg⁻¹ vs placebo and (B) bevacizumab 15 mg kg⁻¹ vs placebo. Hazard ratio shows the comparison of bevacizumab vs placebo. Median cutoff values: VEGF-A=125.0 pg ml⁻¹; VEGFR-1=70.3 pg ml⁻¹; VEGFR-2=11.0 pg ml⁻¹; E-selectin=35.7 ng ml⁻¹; VCAM-1=577.0 ng ml⁻¹; ICAM-1=223.0 ng ml⁻¹. ICAM-1=intracellular adhesion molecule 1; VCAM-1=vascular cell adhesion molecule 1; VEGF-A=vascular endothelial growth factor A; VEGFR-1=vascular endothelial growth factor receptor 1.